Skip to content
Search

Latest Stories

Government accepts JCVI advice on COVID-19 and flu vaccination programmes

Government accepts JCVI advice on COVID-19 and flu vaccination programmes

The government will continue to provide COVID-19 vaccinations to frontline health and social care staff and care home workers in the autumn 2024 programme

The government has accepted the Joint Committee on Vaccination and Immunisation's (JCVI) advice for the autumn 2024 COVID-19 vaccination programme.


According to the JCVI, the following groups will be eligible for vaccination this autumn:

  • Individuals aged 65 and over
  • Residents of care homes for older adults
  • Those aged 6 months and older in clinical risk groups

Minister for Public Health and Prevention, Andrew Gwynne, emphasised the importance of protecting vulnerable populations from COVID-19 and reducing pressure on the NHS.

He said: “We are committed to protecting those most vulnerable from COVID and have accepted the independent advice from the JCVI for the autumn 2024 vaccination programme.”

“I encourage anyone invited for a vaccine to get one as soon as possible to protect yourself and reduce pressure on the NHS during winter, helping to cut waiting times and get the health service back on its feet.”

Additionally, Gwynne announced that the government will continue to offer COVID-19 vaccinations to frontline NHS and social care workers and staff in care homes for older people this autumn.

The JCVI did not recommend including frontline health and social care workers, staff in care homes for older adults, unpaid carers, and household contacts of immunosuppressed individuals in the national programme.

The JCVI suggested that health and social care service providers consider setting up an occupational health vaccination programme for frontline workers, similar to the existing flu vaccine programme.

However, since implementing a new occupational health programme before autumn 2024 is not feasible, the JCVI recommended that health departments might opt to continue offering vaccinations through the national programme this autumn.

Consequently, the government has decided to maintain the provision of COVID-19 vaccinations to frontline health and social care staff, as well as staff working in care homes for older people, in the autumn 2024 programme.

Earlier, the JCVI advised NHS England to move the start of the flu vaccination programme for most adults to the beginning of October.

This change is based on evidence showing that the flu vaccine’s effectiveness can decrease over time in adults.

The goal is to complete the majority of vaccinations by the end of November, aligning more closely with the start of the flu season.

Bases on this advice, NHS England has confirmed the following start dates for the commencement of the service for pharmacies and general practices:

  • 1st September 2024: Pregnant women
  • 3rd October 2024: All other eligible adult patients

In previous years, flu vaccinations have been offered from September.

The NHS will not cover the cost of vaccinations administered outside these specified dates.

Pharmacy teams should inform their patients about the later start to the programme and the reasons behind NHS England's decision.

Community Pharmacy England has developed a poster to help communicate this information in pharmacies.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less